Table 1 Patient characteristics
| Â | Unmatched cNSCLC | Matched cNSCLC | uNSCLC | p-value |
|---|---|---|---|---|
|  | (n = 131) | (n = 44) | (n = 44) | |
Age, years | 69 (43–83) | 67 (44–81) | 66 (40–83) | 0.923 |
Sex, men | 103 (79) | 42 (95) | 42 (95) | 1.000 |
Smoking status, ever-smokers | 111 (85) | 42 (95) | 42 (95) | 1.000 |
EGOG-PS, | Â | Â | Â | 0.237 |
 0 | 69 (53) | 21 (48) | 14 (32) |  |
 58 (44) | 19 (43) | 22 (50) |  |  |
 ≥ 2 | 4 (3) | 4 (9) | 8 (18) |  |
Stage, | Â | Â | Â | 0.715 |
 III | 23 (18) | 14 (32) | 14 (32) |  |
 IV | 97 (74) | 24 (55) | 21 (48) |  |
Recurrence | 11 (8) | 6 (14) | 9 (20) | Â |
Metastases, | Â | Â | Â | Â |
 Brain | 26 (20) | 14 (32) | 8 (18) | 0.218 |
 Liver | 13 (10) | 4 (9) | 10 (23) | 0.143 |
 Bone | 30 (23) | 11 (25) | 16 (36) | 0.355 |
Pathology, |  |  |  | < 0.001 |
 Adenocarcinoma | 85 (65) | 32 (73) | 0 (0) |  |
 Squamous cell carcinoma | 46 (35) | 12 (27) | 0 (0) |  |
 Pleomorphic carcinoma | 0 (0) | 0 (0) | 10 (23) |  |
 LCNEC | 0 (0) | 0 (0) | 9 (20) |  |
 Large cell carcinoma | 0 (0) | 0 (0) | 2 (5) |  |
 Not otherwise specified | 0 (0) | 0 (0) | 23 (52) |  |
PD-L1: TPS, | Â | Â | Â | 0.942 |
 ≥ 50% | 20 (15) | 15 (34) | 17 (39) |  |
 1–49% | 20 (15) | 12 (27) | 10 (23) |  |
 < 1% | 16 (12) | 5 (11) | 6 (14) |  |
 NA | 75 (57) | 12 (27) | 11 (25) |  |
Line of treatments, | Â | Â | Â | 0.209 |
 1st | 7 (5) | 6 (14) | 7 (16) |  |
 2nd | 61 (47) | 15 (34) | 22 (50) |  |
 ≥ 3rd | 63 (48) | 23 (52) | 15 (34) |  |
Treatments, |  |  |  | < 0.001 |
 Nivolumab | 123 (94) | 37 (84) | 22 (50) |  |
 Pembrolizumab | 8 (6) | 7 (16) | 16 (36) |  |
 Atezolizumab | 0 (0) | 0 (0) | 6 (14) |  |